Treatment response and long-term outcome of peginterferon α and ribavirin therapy in Korean patients with chronic hepatitis C

Chang Ho Jung, Soon-Ho Um, Tae Hyung Kim, Sun Young Yim, Sang Jun Suh, Hyung Joon Yim, Yeon Seok Seo, Hyuk Soon Choi, Hoon-Jai Chun

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background/Aims: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in Korean patients with CHC, particularly in relation to the stage of liver fibrosis. Methods: The incidence of sustained virological response (SVR), hepatic decompensation, hepatocellular carcinoma, and liver-related death was analyzed in 304 patients with CHC; the patients were followed up for a median of 54 months. Results: Among patients with HCV genotype 1, the SVR rate was 36.7% (18/49) and 67% (69/103) for patients with and without cirrhosis, respectively (p<0.001). For patients with non-1 HCV genotypes, the SVR rates were 86.0% (37/43) in cirrhotic patients and 86.2% (94/109) in noncirrhotic patients. SVR significantly reduced the risk of liverrelated death, hepatic decompensation, and hepatocellular carcinoma, which had hazard ratios of 0.27, 0.16, and 0.22, respectively (all p<0.05). However, despite the SVR rate, patients with advanced fibrosis were still at risk of developing liver-related complications. Conclusions: A relatively high SVR rate was achieved by peginterferon plus ribavirin therapy in Korean patients with CHC, which improved their long-term outcomes. However, all CHC patients with advanced hepatic fibrosis should receive close follow-up observations, even after successful antiviral treatment.

Original languageEnglish
Pages (from-to)808-817
Number of pages10
JournalGut and Liver
Volume10
Issue number5
DOIs
Publication statusPublished - 2016 Sep 1

Fingerprint

Ribavirin
Chronic Hepatitis C
Therapeutics
Liver
Fibrosis
Hepatocellular Carcinoma
Genotype
Korea
Liver Cirrhosis
Antiviral Agents

Keywords

  • Clinical
  • Hepatitis C
  • Hepatitis C virus clinical trials
  • Hepatitis C virus treatment
  • Viral hepatitis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Treatment response and long-term outcome of peginterferon α and ribavirin therapy in Korean patients with chronic hepatitis C. / Jung, Chang Ho; Um, Soon-Ho; Kim, Tae Hyung; Yim, Sun Young; Suh, Sang Jun; Yim, Hyung Joon; Seo, Yeon Seok; Choi, Hyuk Soon; Chun, Hoon-Jai.

In: Gut and Liver, Vol. 10, No. 5, 01.09.2016, p. 808-817.

Research output: Contribution to journalArticle

@article{279c59b85d454336a9bcd58734b06db2,
title = "Treatment response and long-term outcome of peginterferon α and ribavirin therapy in Korean patients with chronic hepatitis C",
abstract = "Background/Aims: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in Korean patients with CHC, particularly in relation to the stage of liver fibrosis. Methods: The incidence of sustained virological response (SVR), hepatic decompensation, hepatocellular carcinoma, and liver-related death was analyzed in 304 patients with CHC; the patients were followed up for a median of 54 months. Results: Among patients with HCV genotype 1, the SVR rate was 36.7{\%} (18/49) and 67{\%} (69/103) for patients with and without cirrhosis, respectively (p<0.001). For patients with non-1 HCV genotypes, the SVR rates were 86.0{\%} (37/43) in cirrhotic patients and 86.2{\%} (94/109) in noncirrhotic patients. SVR significantly reduced the risk of liverrelated death, hepatic decompensation, and hepatocellular carcinoma, which had hazard ratios of 0.27, 0.16, and 0.22, respectively (all p<0.05). However, despite the SVR rate, patients with advanced fibrosis were still at risk of developing liver-related complications. Conclusions: A relatively high SVR rate was achieved by peginterferon plus ribavirin therapy in Korean patients with CHC, which improved their long-term outcomes. However, all CHC patients with advanced hepatic fibrosis should receive close follow-up observations, even after successful antiviral treatment.",
keywords = "Clinical, Hepatitis C, Hepatitis C virus clinical trials, Hepatitis C virus treatment, Viral hepatitis",
author = "Jung, {Chang Ho} and Soon-Ho Um and Kim, {Tae Hyung} and Yim, {Sun Young} and Suh, {Sang Jun} and Yim, {Hyung Joon} and Seo, {Yeon Seok} and Choi, {Hyuk Soon} and Hoon-Jai Chun",
year = "2016",
month = "9",
day = "1",
doi = "10.5009/gnl15360",
language = "English",
volume = "10",
pages = "808--817",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "5",

}

TY - JOUR

T1 - Treatment response and long-term outcome of peginterferon α and ribavirin therapy in Korean patients with chronic hepatitis C

AU - Jung, Chang Ho

AU - Um, Soon-Ho

AU - Kim, Tae Hyung

AU - Yim, Sun Young

AU - Suh, Sang Jun

AU - Yim, Hyung Joon

AU - Seo, Yeon Seok

AU - Choi, Hyuk Soon

AU - Chun, Hoon-Jai

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background/Aims: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in Korean patients with CHC, particularly in relation to the stage of liver fibrosis. Methods: The incidence of sustained virological response (SVR), hepatic decompensation, hepatocellular carcinoma, and liver-related death was analyzed in 304 patients with CHC; the patients were followed up for a median of 54 months. Results: Among patients with HCV genotype 1, the SVR rate was 36.7% (18/49) and 67% (69/103) for patients with and without cirrhosis, respectively (p<0.001). For patients with non-1 HCV genotypes, the SVR rates were 86.0% (37/43) in cirrhotic patients and 86.2% (94/109) in noncirrhotic patients. SVR significantly reduced the risk of liverrelated death, hepatic decompensation, and hepatocellular carcinoma, which had hazard ratios of 0.27, 0.16, and 0.22, respectively (all p<0.05). However, despite the SVR rate, patients with advanced fibrosis were still at risk of developing liver-related complications. Conclusions: A relatively high SVR rate was achieved by peginterferon plus ribavirin therapy in Korean patients with CHC, which improved their long-term outcomes. However, all CHC patients with advanced hepatic fibrosis should receive close follow-up observations, even after successful antiviral treatment.

AB - Background/Aims: Peginterferon plus ribavirin remains a standard therapy for patients with chronic hepatitis C (CHC) in Korea. We investigated the efficacy and long-term outcome of peginterferon and ribavirin therapy in Korean patients with CHC, particularly in relation to the stage of liver fibrosis. Methods: The incidence of sustained virological response (SVR), hepatic decompensation, hepatocellular carcinoma, and liver-related death was analyzed in 304 patients with CHC; the patients were followed up for a median of 54 months. Results: Among patients with HCV genotype 1, the SVR rate was 36.7% (18/49) and 67% (69/103) for patients with and without cirrhosis, respectively (p<0.001). For patients with non-1 HCV genotypes, the SVR rates were 86.0% (37/43) in cirrhotic patients and 86.2% (94/109) in noncirrhotic patients. SVR significantly reduced the risk of liverrelated death, hepatic decompensation, and hepatocellular carcinoma, which had hazard ratios of 0.27, 0.16, and 0.22, respectively (all p<0.05). However, despite the SVR rate, patients with advanced fibrosis were still at risk of developing liver-related complications. Conclusions: A relatively high SVR rate was achieved by peginterferon plus ribavirin therapy in Korean patients with CHC, which improved their long-term outcomes. However, all CHC patients with advanced hepatic fibrosis should receive close follow-up observations, even after successful antiviral treatment.

KW - Clinical

KW - Hepatitis C

KW - Hepatitis C virus clinical trials

KW - Hepatitis C virus treatment

KW - Viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=84990042015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990042015&partnerID=8YFLogxK

U2 - 10.5009/gnl15360

DO - 10.5009/gnl15360

M3 - Article

VL - 10

SP - 808

EP - 817

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 5

ER -